Compounds > 2-(4-fluorophenyl)-6-methoxy-1,3-benzothiazole

Page last updated: 2024-11-12

2-(4-fluorophenyl)-6-methoxy-1,3-benzothiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	12179987
CHEMBL ID	490083
CHEBI ID	92442
SCHEMBL ID	1572680

Synonyms (16)

Synonym
smr000486380
MLS001065901
2-(4-fluorophenyl)-6-methoxybenzo[d]thiazole
CHEMBL490083 ,
6-methoxy-2-(4''-fluorophenyl)-1,3-benzothiazole
bdbm50293110
HMS2193K20
HMS3332P21
2-(4-fluorophenyl)-6-methoxybenzothiazole
6-methoxy-2-(4'-fluorophenyl)benzothiazole
2-(4-fluorophenyl)-6-methoxy-1,3-benzothiazole
FFMONRZWRJLZNE-UHFFFAOYSA-N
SCHEMBL1572680
CHEBI:92442
Q27164177
PD148318

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
benzothiazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	19.9526	0.1000	20.8793	79.4328	AID588456
BRCA1	Homo sapiens (human)	Potency	1.2589	0.8913	7.7225	25.1189	AID624202
chromobox protein homolog 1	Homo sapiens (human)	Potency	56.2341	0.0060	26.1688	89.1251	AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	0.5805	0.0041	9.9848	25.9290	AID504444
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	100.0000	0.4256	12.0591	28.1838	AID504891
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	3.9811	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	3.9811	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	3.9811	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	29.0929	0.0046	11.3741	33.4983	AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferin 4-monooxygenase	Photinus pyralis (common eastern firefly)	IC50 (µMol)	1.3000	0.0589	3.1426	10.0000	AID366891
Luciferin 4-monooxygenase	Photuris pensylvanica (Pennsylania firefly)	IC50 (µMol)	25.4300	0.8600	1.1300	1.4000	AID366890; AID366892
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
MSH	Drosophila melanogaster (fruit fly)	AC50	2.3500	0.2090	9.5788	48.6900	AID743444
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID347533	Displacement of [125I]IMPY from beta-amyloid plaques in Alzheimer's disease patient brain homogenate	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
AID366892	Inhibition of luciferin binding site of Photuris pennsylvanica luciferase by competitive KinaseGlo luminescent assay	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution.
AID366893	Inhibition of luciferin binding site of Photuris pennsylvanica luciferase by competitive KinaseGlo Plus luminescent assay	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution.
AID366894	Inhibition of luciferin binding site of Photuris pennsylvanica luciferase by competitive KinaseGlo Plus Max luminescent assay	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution.
AID366891	Inhibition of luciferin binding site of Photinus pyralis luciferase by competitive inhibition assay	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution.
AID366890	Inhibition of luciferin binding site of Photuris pennsylvanica luciferase by competitive inhibition assay	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution.
AID347534	Partition coefficient, log P at pH 7.4	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (50.00)	29.6817
2010's	2 (33.33)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.41 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.36 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
2-(4'-chlorophenyl)benzothiazole [no description available]	2.05	1	0
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole: an amyloid imaging agent; structure in first source	2.05	1	0
sib 1757 SIB 1757: a selective mGluR5 antagonist; structure in first source	2.05	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Amyloid Deposits [description not available]	0	2.05	1	0
Acute Confusional Senile Dementia [description not available]	0	2.05	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	2.05	1	0
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0